DEADLINE ALARM for ALIZY, IVVD, RVYL and SQ: The Law Offices of Frank…

DEADLINE ALARM for ALIZY, IVVD, RVYL and SQ: The Law Offices of Frank…

Facebook
Twitter
LinkedIn

LOS ANGELES, March 21, 2023 (GLOBE NEWSWIRE) — The law office of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders in the following public companies. Investors have until the deadlines listed below to file a lead plaintiff filing.

Investors who experience losses on their investments are encouraged to contact The Law Offices of Frank R. Cruz to discuss their legal rights in these class actions at 310-914-5007 or by email at fcruz@frankcruzlaw.com.

Allianz SE ALIZALIZF))
Class period: March 9, 2018 – May 17, 2022
Deadline for lead plaintiff: April 3, 2023

The Complaint filed in this Class Action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements and failed to disclose material adverse facts about the Company’s business, operations and prospects. Specifically, the defendants failed to disclose to investors that: (1) Allianz did not have effective internal controls; (2) the Allianz subsidiary was involved in significant fraudulent activity; (3) as a result, Allianz faced an increased risk of regulatory scrutiny; (4) as a result, Allianz faced an increased risk of significant losses and financial costs; and (5) as a result, the defendants’ positive statements about the Company’s business, operations and prospects were materially misleading and/or lacking a reasonable basis at all relevant times.

If you are an Alliance shareholder who has suffered a loss, click Here participate.

Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. IVVD
Class Period: November 29, 2021 – December 14, 2021
Deadline for lead plaintiff: April 3, 2023

The Complaint filed in this Class Action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements and failed to disclose material adverse facts about the Company’s business, operations and prospects. Specifically, Defendants failed to disclose to investors: (1) that the published epitope mapping,…

[ad_2]

Source story

More to explorer